Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
Recruiting
Observational Study
Colorectal Cancer
Adenoma Colon
Adenoma Colon Polyp
Colon Adenoma
Colo-rectal Cancer
Colon Disease
Colon Neoplasm
Lynch Syndrome
Lynch Syndrome I
Lynch Syndrome II
Lynch Syndrome I (Site-specific Colonic Cancer)
LYN Gene Mutation
Mismatch Repair Deficiency
Mismatch Repair Gene Mutation
MLH1 Gene Mutation
MSH2 Gene Mutation
MSH6 Gene Mutation
PMS2 Gene Mutation
EPCAM Gene Mutation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,200 (estimated)
- Sponsor
- San Raffaele University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.
* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
*…
Contacts